SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pfizer Reports Robust Responses for 25-Valent Vaccine Candidate in Phase 2

Pfizer said its investigational 25-valent pneumococcal conjugate vaccine candidate demonstrated robust responses in a Phase 2 pediatric study.

PFE

Related stories